To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
101 Current news of Evotec
rss
4-Antibody AG and Evotec AG Form Strategic Collaboration
05-10-2012
4-Antibody AG and Evotec AG announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service. Evotec’s novel and unique high throughput and high content screening approach coupled with 4-Antibody’s high ...
Evotec Achieves Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi
11-03-2011
Evotec AG announced the achievement of specific success criteria in a multiple target drug discovery collaboration with Shionogi & Co Ltd. and the receipt of two milestone payments. Evotec and Shionogi will continue to collaborate to progress the fragments through the drug discovery ...
Evotec and APEIRON Biologics start next project on the Cbl-b target
10-24-2011
Evotec AG and Apeiron Biologics AG announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy.Cbl-b plays a role in both the adaptive and the innate immune system and its manipulation therefore can effectively ...
Evotec announces second multi-target collaboration with UCB
10-11-2011
Evotec AG announced that it has entered into a second multi year, multi target integrated drug discovery collaboration with UCB in the field of immunology.As part of the collaboration, Evotec will apply their integrated drug discovery expertise and technologies to identify interesting small ...
Evotec acquires remaining 30% of Indian Joint Venture from DIL
10-04-2011
Evotec AG announced that it has signed a Share Purchase Agreement to acquire the remaining 30% of equity of its Joint Venture with DIL Limited, India for €1.7M. The acquisition of DIL's 30% outstanding equity in the joint venture will give Evotec 100% ownership of this subsidiary. Evotec ...
Evotec and Roche agree to develop compound that could slow the progression of Alzheimer's disease
09-07-2011
Evotec AG and Roche AG announced that they have entered into an exclusive worldwide agreement for the development and commercialization of Evotec's MAO-B inhibitor in patients with Alzheimer's disease (AD).Under the terms of the agreement, Roche will pay Evotec an upfront fee of $10 million. ...
Evotec Receives Pre-clinical Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
08-22-2011
Evotec AG announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec. The milestone was achieved for the identification and selection of a compound to be advanced into pre-clinical development within an oncology ...
P2X7 antagonist programme, EVT 401, to a top tier global animal health company partnered
Exclusive license granted to major animal health company for development of Evotec proprietary compound
08-15-2011
Evotec AG announced that it has entered into a world-wide license and collaboration agreement with a top tier animal health company that intends to develop the proprietary Evotec compound EVT401, a selective, small molecule P2X7 antagonist, in the companion animal market. Evotec is entitled ...
Evotec announces multi-target collaboration with UCB in neurodegenerative and neurological diseases
07-08-2011
Evotec AG announced that it has entered into a three year integrated drug discovery collaboration with UCB to identify small molecule modulators of priority biological targets, selected by UCB, involved in CNS disorders. As part of the collaboration, Evotec will apply their integrated drug ...
Evotec Achieves Milestone in an Ion Channel Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
Evotec receives a milestone payment from Ono for the progression of novel ion channel modulators into lead optimization
07-06-2011
Evotec AG announced the achievement of specific success criteria in an ion channel research collaboration with Ono Pharmaceutical Co., Ltd. (Ono) and the receipt of a milestone payment. This collaboration project was initiated in October 2009 to identify small molecules targeting an ion ...
